Regeneron Reports ODYSSEY OUTCOMES Data for Praluent in Post-ACS Patients

Regeneron and Sanofi today presented updated data from the ODYSSEY OUTCOMES trial evaluating Praluent (alirocumab) in patients with recent acute coronary syndrome. The data showed that Praluent significantly reduced the risk of major adverse cardiovascular events compared to placebo, with the greatest benefit observed in patients with the highest baseline LDL cholesterol levels.